Sun Pharmaceutical Industries Limited has shared clinical updates on Fibromun and Nidlegy, with key studies failing to meet primary endpoints while further trials and regulatory ...

Read all the latest news headline updates on Sun Pharma. Get all the Sun Pharma breaking news updates, videos, photostories and more at Business Standard.

India's metabolic therapy market is transforming post-semaglutide patent expiry, shifting to a competitive, volume-driven model. With significant price drops and increased launches, demand is surging ...

Sun Pharma is transitioning its US business from low-margin generics to high-value specialty and innovative therapies.

Sun Pharmaceutical Industries Ltd. 524715 shares inched up 0.04% to 1,795.65 Indian rupees Friday, on what proved to be an all-around poor trading session for the stock market, with the BSE SENSEX ...

Sun Pharmaceutical Industries Ltd. closed 3.03% below its 52-week high of 1,850.95 rupees, which the company reached on May 2nd.

Ozempic patent expiry has triggered a fresh pharma race in India. Sun Pharma, Cipla, and Dr Reddy’s are among 7 players ...

How Dilip Shanghvi turned a Rs 10,000 loan into a $45 billion pharma giant, building Sun Pharma through calculated bets, global acquisitions, and a strategic pivot to specialty drugs.

Last week’s expiry of the patent for semaglutide—the active ingredient in Novo Nordisk’s blockbuster drugs Wegovy and Ozmepic ...

Discover the Sun Pharmaceutical Industries Stock Liveblog, your go-to destination for real-time updates and comprehensive ...

Here's an analysis of the annual report of SUN PHARMA for 2024-25. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of ...